L. Tseng

发表

Canakinumab for the Treatment of Children With Colchicine‐Resistant Familial Mediterranean Fever: A 6‐Month Open‐Label, Single‐Arm Pilot Study

P. Hashkes, R. Brik, Yonatan Butbul-Aviel, 2014, Arthritis & rheumatology.

A 13-week, multicenter, randomized, double-blind study of lumiracoxib in hip osteoarthritis

T. Schnitzer, B. Seriolo, R. Rebuli, 2011, Clinical Rheumatology.

CNS tumoursThe first study of dabrafenib in pediatric patients with BRAF V600–mutant relapsed or refractory low-grade gliomas

B. Geoerger, J. Whitlock, D. Hargrave, 2016 .

Trametinib in pediatric patients with neurofibromatosis type 1 (NF-1)–associated plexiform neurofibroma: A phase I/IIa study.

C. Pratilas, B. Geoerger, J. Whitlock, 2018 .

LGG-46. TRAMETINIB THERAPY IN PEDIATRIC PATIENTS WITH LOW-GRADE GLIOMAS (LGG) WITH BRAF GENE FUSION; A DISEASE-SPECIFIC COHORT IN THE FIRST PEDIATRIC TESTING OF TRAMETINIB

B. Geoerger, C. Moertel, D. Hargrave, 2018, Neuro-Oncology.

Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation–Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study

B. Geoerger, J. Whitlock, D. Hargrave, 2019, Clinical Cancer Research.

A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation–Positive Solid Tumors

C. Pratilas, B. Geoerger, J. Whitlock, 2019, Clinical Cancer Research.

A76: Long‐Term Efficacy of Canakinumab in Childhood Colchicine Resistant Familial Mediterranean Fever

P. Hashkes, R. Brik, S. Lubin, 2014 .

Lumiracoxib Is Effective in the Treatment of Episodic Tension‐Type Headache

E. Packman, L. Tseng, H. Thurston, 2005, Headache.

Efficacy and safety results from a phase I/IIa study of dabrafenib in pediatric patients with BRAF V600–mutant relapsed refractory low-grade glioma.

N. André, B. Geoerger, J. Whitlock, 2018 .